Abbonarsi

Comorbidities of atopic dermatitis—what does the evidence say? - 04/05/23

Doi : 10.1016/j.jaci.2022.12.002 
Jacob P. Thyssen, MD, PhD, DMSc a, b, , Anne-Sofie Halling, MD a, Peter Schmid-Grendelmeier, MD c, Emma Guttman-Yassky, MD, PhD d, Jonathan I. Silverberg, MD, PhD, MPH e
a Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark 
b Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 
c Department of Dermatology, University of Zürich, Zürich, Switzerland 
d Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 
e George Washington University School of Medicine and Health Sciences, Washington, DC 

Corresponding author: Jacob P. Thyssen, MD, PhD, DMSc, Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, 2400 Copenhagen NV, Denmark.Department of DermatologyBispebjerg HospitalUniversity of CopenhagenCopenhagenNV2400Denmark

Abstract

Atopic dermatitis (AD) is a common disease that is associated with atopic and nonatopic comorbidities. There has been a growing interest in this area of AD, because presence or risk of comorbidities can in many ways impact the management of patients with AD. Thus, some treatments for AD may improve its comorbidities as well, whereas others may increase their risk. In this review article, we discuss various comorbidities of AD mostly on the basis of the results of recent multiple systematic reviews and meta-analyses to update readers about this rapidly developing area of dermatology. We emphasize the important information provided by studies presenting both relative risk and absolute risk, and show that AD is associated with, among others, atopic comorbidities such as asthma, rhinitis, and food allergy, nonatopic comorbidities such as ocular, psychiatric, infectious, endocrine, autoimmune, and cardiovascular diseases, and certain cancers. Clinicians need to be aware of these and be cognizant about positive and negative effects of existing and new treatments for AD.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Atopic dermatitis, atopy, asthma, burden, comorbidity, epidemiology

Abbreviations used : AA, AD, AR, CCI, CVD, IBD, JAK, MOF, RA, SR


Mappa


 J.P.T. is supported by an unrestricted grant from the Lundbeck Foundation.
 Disclosure of potential conflict of interest: J. P. Thyssen is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme. A.-S. Halling is a speaker for LEO Pharma and consultant for Coloplast A/S. P. Schmid-Grendelmeier received speaker and consultancy fees from AbbVie, ALK Abello, AstraZeneca, Biomed, Galderma, GlaxoSmithKline, LEO Pharma, Eli Lilly & Co, L’Oréal, Novartis, Pfizer, Pierre Fabre, Roche Pharma, Roche-Posay, Sanofi-Genzyme, Stallergenes, and Thermo Fisher. J. I. Silverberg is a speaker for AbbVie, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; received honoraria as a consultant and/or advisory board member for AbbVie, Afyx, Aobiome, Arena Pharmaceuticals, Asana Biosciences, Aslan Pharmaceuticals, BioMX, Biosion, Bluefin, Bodewell, Boehringer Ingelheim, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly & Co, Galderma, GlaxoSmithKline, Incyte, Kiniksa, LEO Pharma, Luna, Menlo, Novartis, Optum, Pfizer, RAPT Therapeutics, Regeneron, Sanofi-Genzyme, Shaperon, Sidekick Health, Union Therapeutics; and received institutional grants from Galderma and Pfizer. E. Guttman-Yassky is an employee at Mount Sinai; received research funds (grants paid to the institution) from Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boehringer Ingelheim, Cara Therapeutics, Celgene, Eli Lilly & Co, Innovaderm, Kyowa Kirin, LEO Pharma, Novartis, Pfizer, and Regeneron; and is a consultant for AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly & Co, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, LEO Pharma, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron, Sanofi-Genzyme, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB, and Ventyx Biosciences.


© 2022  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 151 - N° 5

P. 1155-1162 - Maggio 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Novel insights into atopic dermatitis
  • Charles F. Schuler, Allison C. Billi, Emanual Maverakis, Lam C. Tsoi, Johann E. Gudjonsson
| Articolo seguente Articolo seguente
  • Biomarkers in atopic dermatitis
  • Daphne Bakker, Marjolein de Bruin-Weller, Julia Drylewicz, Femke van Wijk, Judith Thijs

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.